Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT)
by Danessa Lincoln · The Markets DailyRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
- Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
- Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.
Abbott Laboratories Stock Up 0.5%
NYSE ABT traded up $0.60 during mid-day trading on Wednesday, hitting $124.90. The company’s stock had a trading volume of 7,187,180 shares, compared to its average volume of 5,896,229. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The firm has a market capitalization of $217.18 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 2.06 and a beta of 0.72. The company’s 50 day simple moving average is $126.12 and its 200 day simple moving average is $129.17.
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.30. The business had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.21 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.
Abbott Laboratories Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.
Institutional Trading of Abbott Laboratories
Several large investors have recently modified their holdings of the business. Brighton Jones LLC boosted its position in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Abbott Laboratories by 10.5% in the 1st quarter. Jones Financial Companies Lllp now owns 348,852 shares of the healthcare product maker’s stock worth $45,837,000 after buying an additional 33,081 shares during the last quarter. Kera Capital Partners Inc. raised its stake in Abbott Laboratories by 11.3% during the second quarter. Kera Capital Partners Inc. now owns 2,583 shares of the healthcare product maker’s stock valued at $351,000 after buying an additional 262 shares during the last quarter. HBW Advisory Services LLC grew its position in Abbott Laboratories by 8.0% during the 2nd quarter. HBW Advisory Services LLC now owns 3,524 shares of the healthcare product maker’s stock valued at $479,000 after purchasing an additional 261 shares during the last quarter. Finally, RB Capital Management LLC increased its position in shares of Abbott Laboratories by 1.3% during the second quarter. RB Capital Management LLC now owns 40,683 shares of the healthcare product maker’s stock valued at $5,533,000 after acquiring an additional 518 shares in the last quarter. 75.18% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. Barclays boosted their target price on Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. BTIG Research reiterated a “buy” rating and issued a $145.00 target price on shares of Abbott Laboratories in a research report on Thursday, November 20th. Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Finally, The Goldman Sachs Group upped their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $147.68.
Read Our Latest Stock Report on ABT
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.